Core Viewpoint - The recent stock transfer of Green Leaf Pharmaceutical (02186) indicates a strategic shift in shareholder structure, with significant capital injection planned to strengthen its financial position [1] Group 1: Shareholder Changes - On January 26, a stock transfer occurred from Jianyin International Securities to UBS Securities Hong Kong Limited, with a market value of HKD 454 million, representing 3.88% of the total shares [1] - Following the stock transfer, the ownership structure of Nanjing Green Leaf will be as follows: Shenzhen Green Leaf will hold 70.01%, Nanjing Xinshi 23.34%, Nanjing Xinan 4.32%, and Ningbo Xinda 2.33% [1] Group 2: Capital Injection Agreement - On January 26, an investment agreement was established among Shenzhen Green Leaf, Nanjing Xinshi, Nanjing Xinan, Ningbo Xinda, and Nanjing Green Leaf, where Nanjing Xinan and Ningbo Xinda agreed to provide additional capital totaling RMB 285 million [1] - This capital injection is expected to enhance the operational capabilities and financial stability of Nanjing Green Leaf [1]
绿叶制药(02186)股东将股票由建银国际证券转入UBS Securities Hong Kong Limited 转仓市值4.54亿港元